
Search
Selected Filter
Filter Results
Displaying 121–130 of 512 news results
-
Oct 13, 2022
On World Sight Day 2022, Retina International is presenting data from a report on its study into the Socio-economic Impact of late-stage age-related macular degeneration (AMD) in Bulgaria, Germany, and USA.
-
Oct 10, 2022
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Reports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Oct 3, 2022
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
The company is planning to move the emerging treatment into a pivotal trial
-
Oct 3, 2022
Small data sets present challenges for developing rare disease AI tools
-
Sep 22, 2022
Initiatives to increase engagement and awareness around blinding retinal diseases.
-
Sep 15, 2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Sep 13, 2022
Foundation Fighting Blindness Makes Key Appointments to Leadership Team
Several executives promoted to continue the advancement of the Foundation’s notable research and philanthropic efforts.
-
Sep 8, 2022
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
The company plans to seek FDA approval for the emerging therapy in first quarter of 2023
-
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
Aug 11, 2022
ProQR Seeking to Partner Ophthalmic Programs
The company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner